Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Eiger BioPharmaceuticals, Inc.
We consent to the use of our report dated March 22, 2017, with respect to the consolidated balance sheets of Eiger BioPharmaceuticals, Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity (deficit), and cash flows, for each of the years in the three-year period ended December 31, 2016, incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
San Francisco, California
December 8, 2017
